ISSN: 0973-7510
E-ISSN: 2581-690X
, Hager H. Sayed2, Nayera A. Abd-elhamed2, Nouran Elsedfy2, Amira H. Mohamed2, Hania A. Abdellatif2, Fatmaalzharaa F. Mohamed2, Esraa H. Bahnasawy2, Nayera K. Mousa2, Aml Eisa2,Esraa A. Elshenawy2, Yassmin Z. Basheer2, Esraa H. Sayed2,Farah F. Mohamed2, Walaa R. Ali2, Hadir A. Soliman2,Ashrakt A. Eltabary2, Noorhan M. Sayed2, Nourhan H. Nasr2,Nour S. Khairallah2 and Helal F. Hetta3,4 COVID-19 pandemic, which caused by the newly emerged severe acute respiratory syndrome coronavirus-2 (SARS- CoV-2), puts the entire world in an unprecedented crisis, leaving behind huge human losses and serious socio-economical damages. The clinical spectrum of COVID-19 varies from asymptomatic to multi-organ manifestations. Diabetes mellitus (DM) is a chronic inflammatory condition, which associated with metabolic and vascular abnormalities, increases the risk for SARS-CoV-2 infection, severity and mortality. Due to global prevalence, DM effect on COVID-19 outcomes as well as the potential mechanisms by which DM modulates the host-viral interactions and host-immune responses are discussed in this review. This review also highlights the effects of anti-diabetic drugs on treatment of SARS-CoV-2 infection and vice versa.
COVID-19, diabetes, risk factor, cytokines
© The Author(s) 2021. Open Access. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License which permits unrestricted use, sharing, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.